Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00054418 · ClinicalTrials.gov registry record · Phase 3
Risedronate in Preventing Bone Loss in Premenopausal Women Receiving Chemotherapy for Primary Breast Cancer
A Phase 3 study, sponsored by Alliance for Clinical Trials in Oncology.
- Completed
- Registry status
- Phase 3
- Development phase
- 216
- Enrollment target
NCT00054418: Completed Phase 3 study, sponsored by Alliance for Clinical Trials in Oncology.
NCT00054418 is a Phase 3 study that has completed, run by Alliance for Clinical Trials in Oncology. The registered enrollment target is 216 participants, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (72% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00054418, a Phase 3 study, has completed, sponsored by Alliance for Clinical Trials in Oncology.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 216 participants
- Enrollment target
Study Summary
RATIONALE: Preventing bone loss in patients who are receiving chemotherapy for breast cancer may decrease the risk of fractures and may help patients live more comfortably. It is not yet known whether calcium is more effective with or without risedronate in preventing bone loss. PURPOSE: This randomized phase III trial is studying two forms of calcium with or without risedronate to compare how well they work in preventing bone loss in premenopausal women who are receiving chemotherapy for primary stage I, stage II, stage IIIA, or stage IIIB breast cancer.
Interventions
- OTHER placebo
- DIETARY_SUPPLEMENT vitamin D
- DIETARY_SUPPLEMENT calcium carbonate
- DRUG risedronate sodium
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 216 participants |
| Start Date | 2003-03 |
| Est. Completion | 2008-05 |
| Phase | Phase 3 |
What the finished NCT00054418 record still lists
NCT00054418 is an interventional study that assigns participants to a tested intervention. The registered 216 participants enrollment target is mid-sized for trials with a published cap, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (72% lower).
The record links to 0 conditions, and to 4 interventions - of which placebo is the first listed.
NCT00054418 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00054418 about?
NCT00054418 is a clinical study titled "Risedronate in Preventing Bone Loss in Premenopausal Women Receiving Chemotherapy for Primary Breast Cancer". RATIONALE: Preventing bone loss in patients who are receiving chemotherapy for breast cancer may decrease the risk of fractures and may help patients live more comfortably. It is not yet known whether calcium is more effective with or without risedronate in preventing bone loss. PURPOSE: This rando...
What is the current status of trial NCT00054418?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 216 participants. The study started on 2003-03. Estimated completion is 2008-05.
What interventions are being tested in trial NCT00054418?
The interventions under investigation include: placebo (OTHER), vitamin D (DIETARY_SUPPLEMENT), calcium carbonate (DIETARY_SUPPLEMENT), risedronate sodium (DRUG).
Who is sponsoring clinical trial NCT00054418?
This trial is sponsored by Alliance for Clinical Trials in Oncology, which has 446 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT00054418's enrollment target sits among peer trials
216 1332nd of 2000 higher than 667 of 2,000 other Phase 3 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 3 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02609685 · 216 participants · NA
Active Surveillance of Papillary Thyroid Microcarcinoma
- NCT04994873 · 216 participants · NA
Skills to Enhance Positivity in Suicidal Youth
- NCT05264779 · 216 participants · NA
The Periviable GOALS Decision Support Tool
- NCT05434130 · 216 participants · Phase 2
Modulating Exercise Dosage to Improve Concussion Recovery
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia